Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
AIDS (London, England)|January 12, 2000
Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapyH L Devereux, M Youle, M A Johnson, et al.
The Health Service Journal|February 8, 2000
Health economics. Perfect combinationM Youle, R Weston, P Trueman, et al.
International Journal of STD & AIDS|July 1, 1992
Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infectionC D Summerbell, M Youle, V McDonald, et al.
Pharmacoeconomics|October 28, 1999
A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspectiveL Lacey, M Youle, P Trueman, et al.
AIDS (London, England)|October 1, 1990
Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapyD Smith, S Davies, M Nelson, et al.
AIDS (London, England)|September 1, 1996
Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative GroupA Mocroft, M Youle, B Gazzard, et al.
Drugs|January 1, 1997
Ancillary benefits of Mycobacterium avium-intracellulare complex prophylaxis with clarithromycin in HIV-infected patientsH Jablonowski, G Fätkenheuer, M Youle, et al.
HIV Clinical Trials|October 9, 2001
The cost-effectiveness of triple nucleoside analogue therapy antiretroviral regimens in the treatment of HIV in the United KingdomP Trueman, M Youle, C A Sabin, et al.
Pharmacoeconomics|June 6, 1997
Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infectionJ V Chancellor, A M Hill, C A Sabin, et al.
AIDS Research and Human Retroviruses|August 10, 2000
Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patientsH L Devereux, C Loveday, M Youle, et al.
Pageof 8